Work

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland

Year: 2025

Type: article

Abstract: Purpose: To compare the efficacy and safety of semaglutide and liraglutide over one year in obese Polish patients with type 2 diabetes. Patients and Methods: In this prospective, observational cohort study conducted in Poland in 2024, 460 patients aged 18– 80 were enrolled: 333 received semaglutide (Group 1), and 133 received liraglutide (Group 2). Results: After 12 months, HbA1c levels significantly decreased in both groups: Group 1: from 6.09 ± 1.14% to 5.42 ± 0.82% (mean decrease: 0.67 ± 0.37%, p < 0.0001). Group 2: from 5.78 ± 0.75% to 5.17 ± 0.54% (mean decrease: 0.61 ± 0.28%, p < 0.001). BMI decreased by 5.36 ± 3.45 kg/m² in Group 1 and 4.41 ± 4.63 kg/m² in Group 2 ( p < 0.0001), with greater reduction in Group 1 ( p =0.017). Gastrointestinal adverse effects were most common, including nausea, vomiting, constipation, gastritis, and diarrhea, with higher incidence in Group 1. HbA1c reduction correlated with baseline HbA1c, age, and gender; BMI reduction correlated with baseline HbA1c and BMI. Conclusion: Semaglutide was more effective than liraglutide in reducing HbA1c and BMI. Gastrointestinal symptoms were the most frequent side effects in both groups. Keywords: GLP-1 receptor agonist, semaglutide, liraglutide, obesity, type 2 diabetes A Letter to the Editor has been published for this article .

Source: Diabetes Metabolic Syndrome and Obesity

DOI: 10.2147/dmso.s531697

Authors: Karolina Hoffmann, Michał Michalak, Anna Paczkowska

Institution: Poznan University of Medical Sciences

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,836